Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eflornithine, (S)-. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 0.96 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ARG1 | P05089 | 3/20 | 0.61 |
| ▸ | ARG2 | P78540 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Eflornithine SCHEMBL6779173 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL6779172 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL3022583 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL7208883 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL6779168 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL5051665 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL4809264 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL1397750 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL4510 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL3238104 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | claimed |
| US-11969522-B2 | Use of immune modulators to improve nerve regeneration | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-30 | — | — | US | claimed |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2022-03-24 | — | — | US | claimed |
| US-20170143737-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2017-05-25 | — | — | US | claimed |
| US-20100329976-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2010-12-30 | — | — | US | claimed |
| US-20100322853-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2010-12-23 | — | — | US | claimed |
| US-20100322852-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2010-12-23 | — | — | US | claimed |
| WO-2009114695-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2009-09-17 | — | — | WO | claimed |
| WO-2008157230-A1 | RSK INHIBITORS AS ANTI-ANGIOGENIC THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-12-24 | — | — | WO | claimed |
| US-20080226732-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-09-18 | — | — | US | claimed |
| US-20080107741-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-05-08 | — | — | US | claimed |
| US-20080050461-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-02-28 | — | — | US | claimed |
| EP-1800666-A1 | Nanoparticulate compositions of angiogenesis inhibitors | Elan Pharma International Limited (IE) | 2007-06-27 | — | — | EP | claimed |
| EP-1490030-B1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INT LTD (IE) | 2006-10-25 | — | — | EP | claimed |
| EP-1490030-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | Elan Pharma International Limited (IE) | 2004-12-29 | — | — | EP | claimed |
| US-20040033267-A1 | Nanoparticulate compositions of angiogenesis inhibitors | ELAN PHARMA INTERNATIONAL LTD. | 2004-02-19 | — | — | US | claimed |
| WO-2003080027-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |
| EP-1115696-A1 | METHOD FOR PRODUCING (-)-ALPHA-(DIFLUOROMETHYL)ORNITHINE-MONOHYDROCHLORIDE MONOHYDRATE | Lonza AG (CH) | 2001-07-18 | — | — | EP | claimed |
| WO-2000017153-A1 | METHOD FOR PRODUCING (-)-α-(DIFLUOROMETHYL)ORNITHINE-MONOHYDROCHLORIDE MONOHYDRATE | LONZA AG (CH) | 2000-03-30 | — | — | WO | claimed |
| US-20260144848-A1 | METHOD FOR PREDICTING RESPONSE TO A CANCER TREATMENT | PEPTOMYC, S.L. (ES) | 2026-05-28 | — | — | US | disclosed |
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-4527946-A1 | METHOD FOR PREDICTING THE RESPONSE TO A DUAL SPECIFICITY PROTEIN KINASE TTK INHIBITOR THERAPY | Pangaea Oncology, S.A (ES) | 2025-03-26 | — | — | EP | disclosed |
| EP-3793561-B1 | METHOTREXATE COMPOUNDS FOR USE IN TREATING HIV INFECTIONS | NAT CENTRE FOR CELL SCIENCE (IN) | 2025-03-26 | — | — | EP | disclosed |
| EP-3377068-B1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2025-03-26 | — | — | EP | disclosed |
| EP-4291301-B1 | NON-INVASIVE CANCER TREATMENT | SCIENTIA BIOTECH S L (ES) | 2025-01-15 | — | — | EP | disclosed |
| US-12171821-B2 | Toxoplasma gondii vaccine | WISCONSIN ALUMNI RESEARCH FOUNDATION (WARF) (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | disclosed |
| EP-3484913-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | FUNDACIO PRIVADA INST DINVESTIGACIO ONCOLÒGICA DE VALL HEBRON (ES) | 2024-07-03 | — | — | EP | disclosed |
| US-12023336-B2 | Antiviral drug compounds and composition thereof | NATIONAL CENTRE FOR CELL SCIENCE (IN) | 2024-07-02 | — | — | US | disclosed |
| US-11969522-B2 | Use of immune modulators to improve nerve regeneration | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-30 | — | — | US | disclosed |
| CN-117795341-A | Methods of treating cancer using CD-40 agonists | 埃派斯进美国有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117202966-A | Noninvasive cancer treatment | 科学生物技术有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-109563151-B | Methods and compositions for treating cancer | 瓦尔希伯伦私人肿瘤研究基金会 | 2023-03-07 | — | — | CN | disclosed |
| US-11427621-B2 | Methods and compositions for the treatment of cancer | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2022-08-30 | — | — | US | disclosed |
| EP-4043071-A1 | NON-INVASIVE CANCER TREATMENT | Scientia Biotech S.L. (ES) | 2022-08-17 | — | — | EP | disclosed |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | disclosed |
| US-11191770-B2 | — | — | 2021-12-07 | — | — | US | disclosed |
| US-11179348-B2 | Combination comprising pterostilbene for the treatment of cancer | FUNDACIÓN UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR (ES) | 2021-11-23 | — | — | US | disclosed |
| US-20210196718-A1 | ANTIVIRAL DRUG COMPOUNDS AND COMPOSITION THEREOF | NATIONAL CENTRE FOR CELL SCIENCE (IN) | 2021-07-01 | — | — | US | disclosed |
| US-20210121545-A1 | TOXOPLASMA GONDII VACCINE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2021-04-29 | — | — | US | disclosed |
| US-20210113584-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2021-04-22 | — | — | US | disclosed |
| US-20210023264-A1 | USE OF IMMUNE MODULATORS TO IMPROVE NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-28 | — | — | US | disclosed |
| US-10857156-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2020-12-08 | — | — | US | disclosed |
| EP-2665746-B1 | ANTIBODIES AGAINST THE S100P PROTEIN FOR THE TREATMENT AND DIAGNOSIS OF CANCER | LYKERA BIOMED S A (ES) | 2020-10-28 | — | — | EP | disclosed |
| US-20200247857-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2020-08-06 | — | — | US | disclosed |
| EP-3545966-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron (ES) | 2019-10-02 | — | — | EP | disclosed |
| US-10370434-B2 | Methods and compositions for the treatment of cancer | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2019-08-06 | — | — | US | disclosed |
| US-20190224209-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2019-07-25 | — | — | US | disclosed |
| EP-2994533-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | FUNDACIO PRIVADA INST DINVESTIGACIO ONCOLÒGICA DE VALL HEBRON (ES) | 2019-05-01 | — | — | EP | disclosed |
| US-10273469-B2 | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof | Biosearch, S.A. (ES) | 2019-04-30 | — | — | US | disclosed |
| EP-3019038-B1 | PROBIOTIC BACTERIA COMPRISING METAL OXIDE NANOPARTICLES AND USES THEREOF | BIOSEARCH S A (ES) | 2019-04-10 | — | — | EP | disclosed |
| EP-2580240-B1 | S100A4 ANTIBODIES AND THERAPEUTIC USES THEREOF | LYKERA BIOMED S A (ES) | 2018-11-28 | — | — | EP | disclosed |
| US-20180214390-A1 | COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER | UNIVERSITAT DE VALÈNCIA - ESTUDI GENERAL (ES) | 2018-08-02 | — | — | US | disclosed |
| EP-3338789-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron (ES) | 2018-06-27 | — | — | EP | disclosed |
| US-9914768-B2 | Anti-S100A7 antibodies for the treatment and diagnosis of cancer | LYKERA BIOMED, S.A. (ES) | 2018-03-13 | — | — | US | disclosed |
| EP-3269734-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (ES) | 2018-01-17 | — | — | EP | disclosed |
| US-9868784-B2 | Antibodies against the S100P protein for the treatment and diagnosis of cancer | LYKERA BIOMED SA (ES) | 2018-01-16 | — | — | US | disclosed |
| US-9682098-B2 | Compounds suited as nanocarriers for active agents and their use | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-06-20 | — | — | US | disclosed |
| EP-2984108-B1 | ANTI-S100A7 ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF CANCER | LYKERA BIOMED S A (ES) | 2017-05-31 | — | — | EP | disclosed |
| US-20170143737-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2017-05-25 | — | — | US | disclosed |
| US-9657092-B2 | S100A4 antibodies and therapeutic uses thereof | Hernandez Miguez, Jose Luis (ES) | 2017-05-23 | — | — | US | disclosed |
| US-9533056-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2017-01-03 | — | — | US | disclosed |
| US-20160289307-A1 | ANTI-S100A7 ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF CANCER | LYKERA BIOMED SA (ES) | 2016-10-06 | — | — | US | disclosed |
| US-9427474-B2 | Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20160122415-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (FPIIOVH) (ES) | 2016-05-05 | — | — | US | disclosed |
| US-20160095838-A1 | TARGETED POLYMERIC CONJUGATES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-04-07 | — | — | US | disclosed |
| US-20160090412-A1 | ANTIBODIES AGAINST THE S100P PROTEIN FOR THE TREATMENT AND DIAGNOSIS OF CANCER | LYKERA BIOMED SA (ES) | 2016-03-31 | — | — | US | disclosed |
| US-9283279-B2 | Targeted polymeric conjugates and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-03-15 | — | — | US | disclosed |
| US-9259482-B2 | Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-02-16 | — | — | US | disclosed |
| US-9228011-B2 | Antibodies against the S100P protein for the treatment and diagnosis of cancer | LYKERA BIOMED SA (ES) | 2016-01-05 | — | — | US | disclosed |
| US-20150328330-A1 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-19 | — | — | US | disclosed |
| US-20150320786-A1 | COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE | FREIE UNIVERSITAET BERLIN (DE) | 2015-11-12 | — | — | US | disclosed |
| US-9102595-B2 | Compounds suited as nanocarriers for active agents and their use | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-08-11 | — | — | US | disclosed |
| US-9095618-B2 | Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-08-04 | — | — | US | disclosed |
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2015-07-23 | — | — | US | disclosed |
| US-9062094-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2015-06-23 | — | — | US | disclosed |
| US-20150079097-A1 | S100A4 ANTIBODIES AND THERAPEUTIC USES THEREOF | LYKERA BIOMED SA (ES) | 2015-03-19 | — | — | US | disclosed |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L (ES) | 2015-01-01 | — | — | US | disclosed |
| EP-2818056-A1 | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof | Biosearch S.A. (ES) | 2014-12-31 | — | — | EP | disclosed |
| US-8916152-B2 | S100A4 antibodies and therapeutic uses thereof | LYKERA BIOMED SA (ES) | 2014-12-23 | — | — | US | disclosed |
| EP-2296707-B1 | COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE | FREIE UNIVERSITÄT BERLIN (DE) | 2014-11-12 | — | — | EP | disclosed |
| EP-2801370-A1 | Methods and compositions for the treatment of cancer | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron (ES) | 2014-11-12 | — | — | EP | disclosed |
| US-20140271483-A1 | TARGETED POLYMERIC CONJUGATES AND USES THEREOF | Ramont at Tel-Aviv University Ltd. (IL) | 2014-09-18 | — | — | US | disclosed |
| US-20140212357-A1 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140134111-A1 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-05-15 | — | — | US | disclosed |
| US-8703114-B2 | Conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-04-22 | — | — | US | disclosed |
| US-20140079638-A1 | NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES | Fundacion de la Comunidad Valenciana Centro de Investigacion Principle Felipe (ES) | 2014-03-20 | — | — | US | disclosed |
| US-8673594-B2 | Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis | RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK (US) | 2014-03-18 | — | — | US | disclosed |
| US-8658149-B2 | Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-02-25 | — | — | US | disclosed |
| US-20140050734-A1 | ANTIBODIES AGAINST THE S100P PROTEIN FOR THE TREATMENT AND DIAGNOSIS OF CANCER | LYKERA BIOMED SA (ES) | 2014-02-20 | — | — | US | disclosed |
| US-8586019-B2 | Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-11-19 | — | — | US | disclosed |
| US-20130101592-A1 | S100A4 ANTIBODIES AND THERAPEUTIC USES THEREOF | LYKERA BIOMED SA (ES) | 2013-04-25 | — | — | US | disclosed |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| EP-2457593-A1 | Cyclic RGD peptides of amino acids based on thiazoles or oxazoles as selective antagonists of the alpha-v beta-3 integrin | Lykera Biomed S.A. (ES) | 2012-05-30 | — | — | EP | disclosed |
| US-20110286923-A1 | NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES | Fundacion de la Communidad Valenciana Centro de Investigacion principe felipe (ES) | 2011-11-24 | — | — | US | disclosed |
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20110142764-A1 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-06-16 | — | — | US | disclosed |
| US-20110085979-A1 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-04-14 | — | — | US | disclosed |
| US-20110082090-A1 | COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-04-07 | — | — | US | disclosed |
| EP-2300021-A2 | A CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | Ramot at Tel-Aviv University Ltd. (IL) | 2011-03-30 | — | — | EP | disclosed |
| US-20100329976-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2010-12-30 | — | — | US | disclosed |
| US-20100322853-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2010-12-23 | — | — | US | disclosed |
| US-20100322852-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2010-12-23 | — | — | US | disclosed |
| US-20100216710-A1 | METHODS FOR STIMULATING NERVOUS SYSTEM REGENERATION AND REPAIR BY REGULATING ARGINASE I AND POLYAMINE SYNTHESIS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2010-08-26 | — | — | US | disclosed |
| EP-1490030-B2 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INT LTD (IE) | 2010-07-14 | — | — | EP | disclosed |
| US-7741310-B2 | Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2010-06-22 | — | — | US | disclosed |
| EP-2139461-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | Recepticon Aps (DK) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009141827-A2 | A CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009114695-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2009-09-17 | — | — | WO | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |
| EP-1278537-B1 | COMPOSITIONS FOR STIMULATING NERVOUS SYSTEM REGENERATION AND REPAIR BY REGULATING ARGINASE I AND POLYAMINE SYNTHESIS | UNIV CITY (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008157230-A1 | RSK INHIBITORS AS ANTI-ANGIOGENIC THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080279949-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-11-13 | — | — | US | disclosed |
| WO-2008113364-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | RECEPTICON APS (DK) | 2008-09-25 | — | — | WO | disclosed |
| US-20080226732-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-09-18 | — | — | US | disclosed |
| US-20080220075-A1 | Nanoparticulate compositions of angiogenesis inhibitors | ELAN PHARMA INTERNATIONAL LTD. | 2008-09-11 | — | — | US | disclosed |
| EP-1954714-A2 | HEPATOCYTE GROWTH FACTOR INTRON FUSION PROTEINS | Receptor Biologix, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080107741-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-05-08 | — | — | US | disclosed |
| US-20080050461-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-02-28 | — | — | US | disclosed |
| EP-1800666-A1 | Nanoparticulate compositions of angiogenesis inhibitors | Elan Pharma International Limited (IE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007058776-A2 | HEPATOCYTE GROWTH FACTOR INTRON FUSION PROTEINS | RECEPTOR BIOLOGIX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-1490030-B1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INT LTD (IE) | 2006-10-25 | — | — | EP | disclosed |
| US-20060014695-A1 | Hpma-polyamine conjugates and uses therefore | UNIVERSITY OF MARYLAND, BALTIMORE | 2006-01-19 | — | — | US | disclosed |
| US-20050277699-A1 | Method of decreasing sebum production and pore size | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2005-12-15 | — | — | US | disclosed |
| EP-1490030-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | Elan Pharma International Limited (IE) | 2004-12-29 | — | — | EP | disclosed |
| US-20040033267-A1 | Nanoparticulate compositions of angiogenesis inhibitors | ELAN PHARMA INTERNATIONAL LTD. | 2004-02-19 | — | — | US | disclosed |
| US-20030215428-A1 | A polynucleotide encodes an arginase, a nerve growth factors for treating nervous system disorders, neurodegenerative diseases | RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK | 2003-11-20 | — | — | US | disclosed |
| WO-2003080027-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003066068-A1 | HPMA-POLYAMINE CONJUGATES AND USES THEREFORE | INTRADIGM CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-1278537-A2 | METHODS FOR STIMULATING NERVOUS SYSTEM REGENERATION AND REPAIR BY REGULATING ARGINASE I AND POLYAMINE SYNTHESIS | The Research Foundation of the City University of New York (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6462229-B1 | IT HAS BEEN FOUND THAT (.+-.)-.ALPHA.-DIFLUOROMETHYLORNITHINE CAN BE CLEAVED USING THE COMMERCIALLY OBTAINABLE (-)-O,O'-DI-P-TOLUOYL-L-TARTARIC ACID | LONZA LTD. (CH) | 2002-10-08 | — | — | US | disclosed |
| WO-2001085981-A2 | METHODS FOR STIMULATING NERVOUS SYSTEM REGENERATION AND REPAIR BY REGULATING ARGINASE I AND POLYAMINE SYNTHESIS | RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-1115696-A1 | METHOD FOR PRODUCING (-)-ALPHA-(DIFLUOROMETHYL)ORNITHINE-MONOHYDROCHLORIDE MONOHYDRATE | Lonza AG (CH) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000017153-A1 | METHOD FOR PRODUCING (-)-α-(DIFLUOROMETHYL)ORNITHINE-MONOHYDROCHLORIDE MONOHYDRATE | LONZA AG (CH) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000017153-A1 | METHOD FOR PRODUCING (-)-α-(DIFLUOROMETHYL)ORNITHINE-MONOHYDROCHLORIDE MONOHYDRATE | LONZA AG (CH) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (35 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140212357-A1 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | VEGFA, MVD, FLT1 | ODC1 918/4885BLM 4495/4885LMNA 3467/4885 |
| US-20060014695-A1 | Hpma-polyamine conjugates and uses therefore | VEGFA, HDGF, PDCD1 | ODC1 238/4885BLM 1047/4885LMNA 622/4885 |
| US-11191770-B2 | — | CXCR4, TLR7, CCR7 | ODC1 4426/4885BLM 2415/4885LMNA 2886/4885 |
| US-20110085979-A1 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | VEGFA, MVD, FLT1 | ODC1 918/4885BLM 4495/4885LMNA 3467/4885 |
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | ODC1 820/4885BLM 3105/4885LMNA 1767/4885 |
| US-20100322852-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | ODC1 2757/4885BLM 4615/4885LMNA 3968/4885 |
| US-20140079638-A1 | NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES | VEGFA, FLT4, FLT1 | ODC1 2542/4885BLM 3782/4885LMNA 3583/4885 |
| US-20150328330-A1 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES | VEGFA, BPGM, SOST | ODC1 3469/4885BLM 3960/4885LMNA 3150/4885 |
| US-20110286923-A1 | NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES | VEGFA, FLT4, FLT1 | ODC1 2542/4885BLM 3782/4885LMNA 3583/4885 |
| US-20080107741-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | ODC1 2757/4885BLM 4615/4885LMNA 3968/4885 |
| US-20080050461-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | ODC1 2757/4885BLM 4615/4885LMNA 3968/4885 |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | ODC1 820/4885BLM 3105/4885LMNA 1767/4885 |
| US-20150320786-A1 | COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE | KIT, ABCB1, BCOR | ODC1 582/4885BLM 2237/4885LMNA 1644/4885 |
| US-20170143737-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | ODC1 4402/4885BLM 985/4885LMNA 2902/4885 |
| US-20190224209-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | ODC1 4402/4885BLM 985/4885LMNA 2902/4885 |
| US-20210113584-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | ODC1 4402/4885BLM 985/4885LMNA 2902/4885 |
| US-20080226732-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | ODC1 2757/4885BLM 4615/4885LMNA 3968/4885 |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | ODC1 4402/4885BLM 985/4885LMNA 2902/4885 |
| US-20180214390-A1 | COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER | GSTP1, GGT1, GSTA1 | ODC1 3561/4885BLM 945/4885LMNA 4178/4885 |
| US-10857156-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | ODC1 4402/4885BLM 985/4885LMNA 2902/4885 |
| US-20100329976-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | ODC1 2757/4885BLM 4615/4885LMNA 3968/4885 |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | CXCR3, CXCL12, CXCR4 | ODC1 2659/4885BLM 2727/4885LMNA 4678/4885 |
| US-20080279949-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | ODC1 2757/4885BLM 4615/4885LMNA 3968/4885 |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | CHKA, CHKB, DCK | ODC1 1716/4885BLM 3727/4885LMNA 4596/4885 |
| US-20040033267-A1 | Nanoparticulate compositions of angiogenesis inhibitors | VEGFA, KDR, FLT1 | ODC1 2757/4885BLM 4615/4885LMNA 3968/4885 |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | ODC1 4402/4885BLM 985/4885LMNA 2902/4885 |
| US-20160095838-A1 | TARGETED POLYMERIC CONJUGATES AND USES THEREOF | ACP1, SOST, CD44 | ODC1 3429/4885BLM 3111/4885LMNA 2583/4885 |
| US-11179348-B2 | Combination comprising pterostilbene for the treatment of cancer | GSTP1, GGT1, GSTA1 | ODC1 3561/4885BLM 945/4885LMNA 4178/4885 |
| US-20260144848-A1 | METHOD FOR PREDICTING RESPONSE TO A CANCER TREATMENT | SELE, SELL, SELPLG | ODC1 722/4885BLM 1796/4885LMNA 1507/4885 |
| US-20110082090-A1 | COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE | KIT, ABCB1, BCOR | ODC1 582/4885BLM 2237/4885LMNA 1644/4885 |
| US-20140134111-A1 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES | VEGFA, BPGM, SOST | ODC1 3469/4885BLM 3960/4885LMNA 3150/4885 |
| US-20140271483-A1 | TARGETED POLYMERIC CONJUGATES AND USES THEREOF | ACP1, SOST, CD44 | ODC1 3429/4885BLM 3111/4885LMNA 2583/4885 |
| US-20100322853-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | ODC1 2757/4885BLM 4615/4885LMNA 3968/4885 |
| US-20110142764-A1 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES | VEGFA, BPGM, SOST | ODC1 3469/4885BLM 3960/4885LMNA 3150/4885 |
| US-20080220075-A1 | Nanoparticulate compositions of angiogenesis inhibitors | VEGFA, KDR, FLT1 | ODC1 2757/4885BLM 4615/4885LMNA 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.